Pa Ogasiti 24, 2022, bungwe la US Food and Drug Administration (FDA) lidavomereza ibrutinib kuti azichiza odwala omwe ali ndi zaka zopitilira 1 omwe ali ndi matenda osachiritsika (cGVHD) omwe akulandila Pambuyo pakulephera kwa 1- kapena mizere yambiri. chithandizo chamankhwala.Chizindikiro chovomerezeka chimakhala cha odwala ana, omwe amayankhidwa ndi 60% pa sabata la 25, ndipo mapangidwe a mankhwalawa amaphatikizapo makapisozi, mapiritsi ndi kuyimitsidwa pakamwa.
Ibrutinib, BTK inhibitor co-developed by Pharmacicics/Johnson & Johnson, ndi kinase inhibitor yomwe idavomerezedwa kale kuti ichiritse matenda a lymphocytic leukemia komanso cell lymphoma ndi matenda ena.
Suntech ikuyang'ana pa chitukuko ndi kupanga mankhwala opangira mankhwala ndi ma API pogwiritsa ntchito teknoloji yobiriwira.Pakalipano, kampani yathu yapanga zinthu zitatu zapakatikati za ibrutinib kuphatikizapo C AS: 143900-44-1 , C AS: 330792-70-6 , C AS: 330786-24-8 , zonse zomwe zakhala zikugulitsidwa m'mafakitale a GMP. .Pakati pawo, wapakatikati wa C AS: 143900-44-1 amapangidwa ndi teknoloji-enzymatic technology , yomwe ili ndi ubwino wa chitetezo cha chilengedwe chobiriwira, mtengo wotsika komanso wapamwamba kwambiri.Takulandirani kuti mukambirane ndi kugwirizana!
Nthawi yotumiza: Nov-04-2022